The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 07, 2023
Filed:
Apr. 10, 2018
Applicant:
Sierra Oncology, Inc., Plymouth, MI (US);
Inventors:
Christian Andrew Hassig, San Diego, CA (US);
Bryan William Strouse, Ann Arbor, MI (US);
Ryan James Hansen, San Diego, CA (US);
Kenna Lynn Anderes, Poway, CA (US);
Assignee:
Sierra Oncology, Inc., Plymouth, MI (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61P 35/00 (2006.01); A61K 31/166 (2006.01); A61K 31/4184 (2006.01); A61K 31/4535 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/519 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/166 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/4535 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61P 35/00 (2018.01);
Abstract
Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.